Organon & Co. (OGN) Stock Price, Quote & News

Company Profile

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregna...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 551 430 6900

Website: www.organon.com

Address:

30 Hudson Street, Floor 33, Jersey City, United States

_ROCKET_STOCKZ_ May. 28 at 3:46 PM

$FEMY I bet $OGN will come to buy us 🚀🚀🚀🚀🚀

1 · Reply

SuperGreenToday May. 27 at 8:32 AM

$OGN Share Price: $13.40 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $0.02 – $0.03 Target Zone: $0.04 – $0.05 Potential Upside: 71% ROI Time to Expiration: 141 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LongMoneyMovements May. 13 at 5:26 PM

$SLS $OGN

0 · Reply

BiotechJedi1728 May. 12 at 11:22 PM

$DARE This will likely be approved and someone will swoop in. Maybe the company that bought $OGN will want another women’s health asset. https://www.linkedin.com/posts/positive-interim-phase-3-results-highlight-share-7460079253968117760-MKDN?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_campaign=share_via

0 · Reply

MysticMorpheus May. 10 at 8:05 PM

AMS 💎 If you ain't bullish enough here I don't know what to say! AMS trending #3 on Stocktwits, bullish as it gets. Life changing money will be made here next week, don't be left behind on this opportunity! $XWEL $PMAX $OGN $SXTC ..//

1 · Reply

MysticMorpheus May. 8 at 11:50 PM

AMS 🚨 is the next parabolic runner for next week. Look at AMS go, I think it will pull the biggest run! Don't end up chasing it, be early bulls, I believe AMS has the look! AMS already squeezing!! $OGN $FLNC $GME $ASBP ..122

0 · Reply

Newmoves May. 7 at 9:59 PM

$OGN what is the possibility this acquisition falls through?

0 · Reply

Jackprong May. 4 at 3:39 PM

$OGN I’m out! Made my gains by buying this issue at lower sp and the buyout. Food stocks and REITs will be the ones I accumulate going forward.

1 · Reply

OnlyFibs May. 2 at 8:17 PM

$OGN 40% since alerted and more to come, folks..

0 · Reply

TalkMarkets May. 1 at 6:06 PM

An April To Remember For Stocks $OGN $INTC $SPY $QQQ $DIA https://talkmarkets.com/article/an-april-to-remember-for-stocks-1777658779

0 · Reply

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)

Jun 1, 2026, 8:00 AM EDT - 4 days ago

Organon & Co. Proxy statement: Proxy filing

May 21, 2026, 5:06 AM EDT - 16 days ago

Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia

2026-05-15T11:46:15.000Z - 21 days ago

Organon to present new research at ISPOR 2026

May 15, 2026, 7:30 AM EDT - 21 days ago

Organon to Present New Research on Access and Value at ISPOR 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Organon & Co. Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Organon & Co. Quarterly report: Q1 2026

2026-04-30T12:10:58.000Z - 5 weeks ago

Organon will not provide financial guidance due to pending merger

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 30, 2026, 7:30 AM EDT - 5 weeks ago

Organon Reports Results for the First Quarter Ended March 31, 2026

2026-04-29T12:37:38.000Z - 5 weeks ago

Organon cancels Q1 earnings call

Apr 29, 2026, 7:30 AM EDT - 5 weeks ago

Organon Cancels First Quarter Earnings Call

2026-04-29T09:50:39.000Z - 5 weeks ago

Organon gets European Commission marketing authorization for Poherdy

2026-04-28T12:11:19.000Z - 5 weeks ago

Organon moved to No Rating at BofA

2026-04-28T11:41:54.000Z - 5 weeks ago

Organon downgraded to Neutral from Outperform at BNP Paribas

2026-04-27T20:45:26.000Z - 5 weeks ago

Organon upgraded to Neutral from Underweight at Piper Sandler

2026-04-27T16:08:08.000Z - 5 weeks ago

Organon rises 17.0%

Apr 27, 2026, 11:02 AM EDT - 5 weeks ago

Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical

2026-04-27T14:34:23.000Z - 5 weeks ago

Organon rises 17.2%

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 27, 2026, 5:22 AM EDT - 5 weeks ago

Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.

Apr 27, 2026, 12:19 AM EDT - 5 weeks ago

Why is Sun Pharma betting $11.75B on a struggling US drugmaker?

Apr 26, 2026, 10:13 PM EDT - 5 weeks ago

Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

Apr 26, 2026, 9:16 PM EDT - 5 weeks ago

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

2026-04-27T00:05:07.000Z - 5 weeks ago

Sun Pharma to acquire Organon for $14 per share in all-cash transaction

Apr 26, 2026, 8:01 PM EDT - 5 weeks ago

Sun Pharma to acquire Organon in $11.75 bln all-cash deal

Apr 26, 2026, 7:51 PM EDT - 5 weeks ago

Sun Pharma signs Definitive Agreement to Acquire Organon

2026-04-25T01:38:00.000Z - 6 weeks ago

Organon Stock (OGN) Surges on Reports of a $13B Bid

MRK

2026-04-24T16:07:27.000Z - 6 weeks ago

Organon rises 25.8%

2026-04-24T14:07:05.000Z - 6 weeks ago

Organon rises 22.8%

Apr 24, 2026, 8:00 AM EDT - 6 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 6 weeks ago

Organon & Co. Proxy statement: Proxy filing

Apr 16, 2026, 7:30 AM EDT - 7 weeks ago

Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026

Apr 15, 2026, 7:30 AM EDT - 7 weeks ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

Apr 10, 2026, 10:01 AM EDT - 2 months ago

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring.

Apr 10, 2026, 9:42 AM EDT - 2 months ago

This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works

Apr 10, 2026, 6:26 AM EDT - 2 months ago

These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More.

INTC LITE NVDA

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

ABBV AMRX NVS

Mar 3, 2026, 4:49 AM EST - 3 months ago

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

Feb 27, 2026, 8:00 AM EST - 3 months ago

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

Feb 23, 2026, 7:30 AM EST - 3 months ago

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

Feb 12, 2026, 8:30 AM EST - 4 months ago

Organon & Co. Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:30 AM EST - 4 months ago

Organon & Co. Annual report: Q4 2025

Feb 12, 2026, 8:30 AM EST - 4 months ago

Organon & Co. Earnings release: Q4 2025

Feb 12, 2026, 8:30 AM EST - 4 months ago

Organon & Co. Slides: Q4 2025

Feb 12, 2026, 7:30 AM EST - 4 months ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Jan 29, 2026, 7:30 AM EST - 4 months ago

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Jan 28, 2026, 12:45 PM EST - 4 months ago

Organon Completes Divestiture of JADA® System to Laborie

Jan 16, 2026, 9:12 PM EST - 5 months ago

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Jan 8, 2026, 1:30 AM EST - 5 months ago

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Dec 3, 2025, 10:00 AM EST - 6 months ago

Organon & Co. Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 6 months ago

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 5:30 AM EST - 7 months ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Nov 10, 2025, 8:30 AM EST - 7 months ago

Organon & Co. Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 7 months ago

Organon & Co. Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 7 months ago

Organon & Co. Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 7 months ago

Organon & Co. Slides: Q3 2025

Nov 10, 2025, 7:30 AM EST - 7 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 7, 2025, 7:30 AM EST - 7 months ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 6, 2025, 7:30 AM EST - 7 months ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Oct 27, 2025, 7:44 AM EDT - 7 months ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:30 AM EDT - 7 months ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Sep 19, 2025, 6:00 AM EDT - 9 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 9 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Organon & Co. Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Organon & Co. Earnings release: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Organon & Co. Quarterly report: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Organon & Co. Slides: Q2 2025

Aug 5, 2025, 7:30 AM EDT - 10 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Jul 22, 2025, 7:30 AM EDT - 11 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 21, 2025, 4:02 PM EDT - 11 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

_ROCKET_STOCKZ_ May. 28 at 3:46 PM

$FEMY I bet $OGN will come to buy us 🚀🚀🚀🚀🚀

1 · Reply

SuperGreenToday May. 27 at 8:32 AM

0 · Reply

LongMoneyMovements May. 13 at 5:26 PM

$SLS $OGN

0 · Reply

BiotechJedi1728 May. 12 at 11:22 PM

0 · Reply

MysticMorpheus May. 10 at 8:05 PM

1 · Reply

MysticMorpheus May. 8 at 11:50 PM

0 · Reply

Newmoves May. 7 at 9:59 PM

$OGN what is the possibility this acquisition falls through?

0 · Reply

Jackprong May. 4 at 3:39 PM

$OGN I’m out! Made my gains by buying this issue at lower sp and the buyout. Food stocks and REITs will be the ones I accumulate going forward.

1 · Reply

OnlyFibs May. 2 at 8:17 PM

$OGN 40% since alerted and more to come, folks..

0 · Reply

TalkMarkets May. 1 at 6:06 PM

An April To Remember For Stocks $OGN $INTC $SPY $QQQ $DIA https://talkmarkets.com/article/an-april-to-remember-for-stocks-1777658779

0 · Reply

Alphasearch May. 1 at 3:48 PM

$OGN Sold all of my shares for a loss. Not worth waiting a year holding for .75 more and risk of the deal not going through. Could get a competing bid, but with $8 billion of debt and inept criminal execs not worth the risk. Better fish to fry in a bull market

0 · Reply

yohouoho May. 1 at 1:23 AM

$OGN PURE UNADULTERATED DOG SHIT.

1 · Reply

StocktwitsEarnings Apr. 30 at 11:55 AM

$OGN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.56 up 64.71% YoY • Reported revenue of $1.46B down -3.50% YoY

0 · Reply

Sir_White Apr. 29 at 3:28 PM

$OGN Sold. Not going to wait for a year to get 14. Thanks Organon & Sun Pharma.

0 · Reply

TeresaTrades Apr. 29 at 2:15 PM

Largest CALL OI Decreases $MARA $OGN $CTRA $NUAI $WULF

0 · Reply

briefingcom Apr. 29 at 12:20 PM

$OGN: Organon receives EU approval for first pertuzumab biosimilar https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260429053902OGN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

TristaHarper Apr. 29 at 9:53 AM

$OGN European Commission (EC) approved Henlius / Organon’s POHERDY® (pertuzumab) First biosimilar to PERJETA approved in the European market Key points: • First Perjeta biosimilar approved in the EU • Expanding competition in oncology biologics • Continued progress in Organon biosimilars pipeline

0 · Reply

StocktwitsNews Apr. 29 at 2:25 AM

Why Did NOK, OGN, XE Stocks Hit 52-Week Highs Today? $NOK $OGN $XE https://stocktwits.com/news/equity/markets/why-did-nok-ogn-xe-stocks-hit-52-week-highs-today/cZBqnmTRe32

0 · Reply

jdlman Apr. 28 at 10:53 PM

$OGN cramer says NO

0 · Reply

MrNotSoNice Apr. 28 at 8:40 PM

$OGN Is there and upside left here? Are we maxed out at $14 because of the Sun deal? Time to sell my long? Opinions please. 🤔

1 · Reply

Market Cap	3.52B
Revenue (ttm)	6.22B
Net Income (ttm)	187.00M
EPS (ttm)	N/A
PE Ratio	4.26
Forward PE	4.15
Profit Margin	3.01%
Debt to Equity Ratio	9.49

Volume	2,188,256
Avg Vol	9,952,896
Day's Range	N/A - N/A
Shares Out	262.60M
Stochastic %K	20%
Beta	1.55
Analysts	Hold
Price Target	$10.50